Short answer
Bausch & Lomb Corp (BLCO) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.4B (up 7.3% year over year) with net income of $32M.
Q3 2026 key financials · XBRL
- Revenue
- $1.4B
- +7.3% YoY · −1.4% QoQ
- Net income
- $32M
- +214.3% YoY · +328.6% QoQ
- Operating margin
- 11.3%
- EPS (diluted)
- $0.09
- +228.6% YoY · +325.0% QoQ
Source: XBRL data from the Bausch & Lomb Corp (BLCO) Q3 2026 10-Q on SEC EDGAR. USD.
Bausch & Lomb Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $1,375M, up 7% YoY from $1,281M, driven by volume, pricing and acquisitions
- Cost of goods sold margin 35.4% vs 39.9% YoY, supporting operating income of $155M vs $95M
- Pharmaceuticals strongest growth: revenue $367M, up 11%; Vision Care largest segment at $774M
- Operating cash flow $418M for nine months vs $147M YoY; investing cash use $290M, including $35M MIEBO milestone payment
- Near-term headwinds: evolving tariffs, FDA Tampa warning letter, geopolitical conflicts and healthcare pricing pressure.calc
Risk Factors
- Leadership transition risk: Thomas Appio became interim CEO October 12, 2026, following Brent Saunders’ departure
- Governance conflict risk: Appio’s concurrent Bausch Health CEO role may divide management attention
- Strategic execution risk: New chairman and interim CEO may change business strategy, creating stakeholder uncertainty
- Market risk: Leadership disruption could reduce the market value of common shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.